HANK & LIN'S GROUP

The past is prologue and the future is scintillating

[18F]-FPBM2  :

SERT(5HTT) imaging agents

  1. Journal of Chromatography B 1121 (2019): 28-38.

  2. Nuclear medicine and biology 66 (2018): 1-9.

  3. Journal of Labelled Compounds and Radiopharmaceuticals 61.8 (2018): 576-585.


             Introduction to [18F]-FPBM2: A SERT (5-HTT) Imaging Agent


  • Overview：

    [18F]-FPBM2 is a novel fluorine-18-labeled positron emission tomography (PET) imaging agent designed for the in vivo visualization and quantification of serotonin transporter (SERT, also known as 5-HTT) in the brain. SERT plays a critical role in serotonin (5-HT) reuptake and is implicated in various neuropsychiatric and neurodegenerative disorders, including depression, anxiety, Parkinson’s disease, and Alzheimer’s disease.

  • Mechanism of Action：

    [18F]-FPBM2 is a radiolabeled ligand that selectively binds to SERT in the brain, enabling real-time imaging of serotonin transporter distribution and density using PET. By targeting SERT, [¹⁸F]-FPBM2 allows for non-invasive assessment of serotonergic function, aiding in both research and clinical applications.

  • Conclusion：

    [18F]-FPBM2 represents a promising SERT PET imaging agent with significant potential for advancing neuropsychiatric and neurodegenerative disorder research. Its high selectivity, favorable pharmacokinetics, and broad applications make it a valuable tool for both clinical and preclinical studies.

[18F]-FPBM2 & FPBM : SERT(5HTT) imaging agents


Publications:

1.Liu, F, et al. "Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent." Journal of Labelled Compounds and Radiopharmaceuticals 61.8 (2018): 576-585.

https://doi.org/10.1002/jlcr.3626

2.Zhang, Y., et al. "Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain." Nuclear medicine and biology 66 (2018): 1-9. https://doi.org/10.1016/j.nucmedbio.2018.06.008

3.Sun, M., et al. "Rapid screening of nine unradiolabeled candidate compounds as PET brain imaging agents using cassette-wave microdosing and LC-MS/MS." Journal of Chromatography B 1121 (2019): 28-38. https://doi.org/10.1016/j.jchromb.2019.05.006

4.Zhu, L., et al. "An improved preparation of [18F] FPBM: a potential serotonin transporter (SERT) imaging agent." Nuclear medicine and biology 40.8 (2013): 974-979. https://doi.org/10.1016/j.nucmedbio.2013.08.002

5.Qiao, H., et al. "One-step preparation of [18F] FPBM for PET imaging of serotonin transporter (SERT) in the brain." Nuclear medicine and biology 43.8 (2016): 470-477. https://doi.org/10.1016/j.nucmedbio.2016.04.003

6.Xiao, H., et al. "Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening." Journal of pharmaceutical and biomedical analysis 154 (2018): 48-56. https://doi.org/10.1016/j.jpba.2018.02.063

7.Wang, JL., et al. "In vivo studies of the SERT-selective [18F] FPBM and VMAT2-selective [18F] AV-133 radiotracers in a rat model of Parkinson's disease." Nuclear medicine and biology 37.4 (2010): 479-486. https://doi.org/10.1016/j.nucmedbio.2010.01.006